The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occuring in children with Down syndrome

Leukemia
C LanzaG Saglio

Abstract

Individuals with constitutional trisomy 21 (Down syndrome) are at increased risk of developing acute leukaemias, both of myeloid and lymphoid lineage. Although the cause of leukaemia in Down syndrome (DS) remains unknown, potential candidate genes include the ones on chromosome 21, and in particular AML1, the rearrangement of which in the t(8,21) is associated with the French-American-British (FAB) classification M2 subtype of acute myeloid leukaemia (AML) in the general population and has been described in Down patients with AML-M2. Recently, a new rearrangement involving AML1, the t(12;21), producing the TEL/AML1 hybrid transcript, has been described by molecular analysis as the most recurrent genetic lesion in childhood acute lymphoblastic leukemia (ALL). In order to investigate whether the t(12;21) could give a molecular clue as to the precise basis of the etiologic association between DS and acute lymphoblastic leukemia, we tested a series of 11 consecutive cases of ALL in DS children for the presence of the TEL/AML1 transcript, by RT-PCR analysis. We report absence of the TEL/AML1 rearrangement among the 11 cases tested. This data may be suggestive of alternative pathways involved in the pathogenesis of ALL in children wi...Continue Reading

Citations

Sep 16, 2004·Pediatric Blood & Cancer·Mylène BassalLinda C Stork
Apr 13, 1999·Cancer Genetics and Cytogenetics·D H SpathasJ M Connor
Sep 25, 2001·Archives of Disease in Childhood·J M ChessellsI M Hann
Jul 16, 2005·Pediatric Hematology and Oncology·Manuel SteinerUNKNOWN Austrian Berlin-Frankfurt-Münster Group
Mar 18, 2005·Pediatric Hematology and Oncology·Manuel SteinerGeorg Mann
Feb 2, 2010·Hematology/oncology Clinics of North America·C Michel ZwaanParesh Vyas
Feb 5, 2008·Pediatric Clinics of North America·Michel C ZwaanParesh Vyas
Oct 24, 2006·British Journal of Haematology·James A Whitlock
Oct 19, 2006·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·Natalia DixonSherri Zimmerman
Apr 24, 2004·Cancer Genetics and Cytogenetics·Pornthep Tiensiwakul
May 25, 2004·Oncogene·Ewan R Cameron, James C Neil
Jul 3, 2002·Nature Reviews. Cancer·Nancy A Speck, D Gary Gilliland
Sep 10, 2004·Leukemia·A AttarbaschiUNKNOWN Austrian Berlin-Frankfurt-Münster cooperative study group
Mar 25, 2014·International Journal of Language & Communication Disorders·Glynis Laws, Amanda Hall

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.